Evaluation of Fluorescence- and Mass Spectrometry—Based CYP Inhibition Assays for Use in Drug Discovery

Abstract

The potential for metabolism-related drug-drug interactions by new chemical entities is assessed by monitoring the impact of these compounds on cytochrome P450 (CYP) activity using well-characterized CYP substrates. The conventional gold standard approach for in vitro evaluation of CYP inhibitory potential uses pooled human liver microsomes (HLM) in conjunction with prototypical drug substrates, often quantified by LC-MS/MS. However, fluorescent CYP inhibition assays, which use recombinantly expressed CYPs and fluorogenic probe substrates, have been employed in early drug discovery to provide low-cost, high-throughput assessment of new chemical entities. Despite its greatly enhanced throughput, this approach has been met with mixed success in predicting the data obtained with the conventional gold standard approach (HLM+LC-MS). The authors find that the predictivity of fluorogenic assays for the major CYP isoforms 3A4 and 2D6 may depend on the quality of the test compounds. Although the structurally more optimized marketed drugs yielded acceptable correlations between the fluorogenic and HLM+LC-MS/MS assays for CYPs 3A4, 2D6, and 2C9 (r ² = 0.5-0.7; p < 0.005), preoptimization, early discovery compounds yielded poorer correlations (r ² ≤ 0.2) for 2 of these major isoforms, CYPs 3A4 and 2D6. Potential reasons for the observed differences are discussed. (Journal of Biomolecular Screening 2008;343-353)

Keywords

CYP inhibition fluorogenic substrates drug safety screening human liver microsomes drug-drug interactions

References

Obach RS , Walsky RL , Venkatakrishnan K. , Gaman EA , Houston JB , Tremaine LM : The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions. J Pharmacol Exp Ther 2006; 316:336-348.

Patsalos PN , Perucca E. : Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs. Lancet Neurol 2003; 2:473-481.

Wienkers LC , Heath TG : Predicting in vivo drug interactions from in vitro drug discovery data. Nat Rev Drug Discov 2005;4:825-833.

Tucker GT , Houston JB , Huang SM : Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential- towards a consensus. Br J Clin Pharmacol 2001;52:107-117.

Bjornsson TD , Callaghan JT , Einolf HJ , Fischer V. , Gan L. , Grimm S. , et al: The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos 2003;31:815-832.

Lazarou J. , Pomeranz BH , Corey PN : Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998;279:1200-1205.

Kim M. , Kim H. , Cha I. , Park J. , Shon J. , Liu K. , et al: High-throughput screening of inhibitory potential of nine cytochrome P450 enzymes in vitro using liquid chromatography/tandem mass spectrometry . Rapid Commun Mass Spectrom 2005;19:2651-2658.

Stresser DM , Blanchard AP , Turner SD , Erve JC , Dandeneau AA , Miller VP , et al: Substrate-dependent modulation of CYP3A4 catalytic activity: analysis of 27 test compounds with four fluorometric substrates. Drug Metab Dispos 2000;28:1440-1448.

Crespi CL , Miller VP , Penman BW : Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450. Anal Biochem 1997; 248:188-190.

10.

Miller VP , Stresser DM , Blanchard AP , Turner S. , Crespi CL : Fluorometric high-throughput screening for inhibitors of cytochrome P450. Ann N Y Acad Sci 2000;919:26-32.

11.

Friden M. , Vanaja K. , Nandi VN : Drug-drug interactions of anti-infective drugs: utility of fluorescence cyp inhibition assays in drug discovery. Drug Metab Drug Interact 2006;21:163-185.

12.

Cohen LH , Remley MJ , Raunig D. , Vaz A. : In vitro drug interactions of cytochrome P450: an evaluation of fluorogenic to conventional substrates. Drug Metab Dispos 2003;31:1005-1015.

13.

Kenworthy KE , Bloomer JC , Clarke SE , Houston JB : CYP3A4 drug interactions: correlation of 10 in vitro probe substrates. Br J Clin Pharmacol 1999;48:716-727.

14.

Wang J. , Urban L. , Bojanic D. : Maximising use of in vitro ADMET tools to predict in vivo bioavailability and safety. Expert Opin Drug Metab Toxicol 2007;3:641-665.

15.

Yamamoto T. , Suzuki A. , Kohno Y. : Application of microtiter plate assay to evaluate inhibitory effects of various compounds on nine cytochrome P450 isoforms and to estimate their inhibition patterns. Drug Metab Pharmacokinet 2002;17:437-448.

16.

Papoulis A. : Probability and Statistics. Englewood Cliffs, NJ : Prentice Hall, 1990.

17.

Nomeir A. , Ruegg C. , Shoemaker M. , Favreau L. , Palamanda J. , Silber P. , et al: Inhibition of CYP3A4 in a rapid microtiter plate assay using recombinant enzyme and in human liver microsomes using conventional substrates . Drug Metab Dispos 2001;29:748-753.

18.

Wienkers LC : Factors confounding the successful extrapolation of in vitro CYP3A inhibition information to the in vivo condition. Eur J Pharm Sci 2002;15:239-242.

19.

Shou M. , Mei Q. , Ettore MW Jr , Dai R. , Baillie TA , Rushmore TH : Sigmoidal kinetic model for two co-operative substrate-binding sites in a cytochrome P450 3A4 active site: an example of the metabolism of diazepam and its derivatives. Biochem J 1999;340:845-853.

20.

Shou M. , Dai R. , Cui D. , Korzekwa KR , Baillie TA , Rushmore TH : A kinetic model for the metabolic interaction of two substrates at the active site of cytochrome P450 3A4. J Biol Chem 2001 ;276:2256-2262.

21.

Kenworthy KE , Clarke SE , Andrews J. , Houston JB : Multisite kinetic models for CYP3A4: simultaneous activation and inhibition of diazepam and testosterone metabolism. Drug Metab Dispos 2001;29:1644-1651.

22.

Lu P. , Lin Y. , Rodriques AD , Rushmore TH , Baillie TA , Shou M. : Testosterone, 7-benzyloxyquinoline, and 7-benzyloxy-4-trifluoromethyl-coumarin bind to different domains within the active site of cytochrome P450 3A4. Drug Metab Dispos 2001;29:1473-1479.

23.

Shimada T. , Gillam EM , Sandhu P. , Guo Z. , Tukey RH , Guengerich FP : Activation of procarcinogens by human cytochrome P450 enzymes expressed in Escherichia coli: simplified bacterial systems for genotoxicity assays . Carcinogenesis 1994;15:2523-2529.

24.

Li DN , Pritchard MP , Hanlon SP , Burchell B. , Wolf CR , Friedberg T. : Competition between cytochrome P-450 isozymes for NADPH-cytochrome P-450 oxidoreductase affects drug metabolism. J Pharmacol Exp Ther 1999;289:661-667.

25.

Kelley RW , Reed JR , Backes WL : Effects of ionic strength on the functional interactions between CYP2B4 and CYP1A2. Biochemistry 2005; 44:2632-2641.

26.

Gao F. , Johnson DL , Ekins S. , Janiszewski J. , Kelly KG , Meyer RD , West M. : Optimizing higher throughput methods to assess drug-drug interactions for CYP1A2, CYP2C9, CYP2C19, CYP2D6, rCYP2D6 and CYP3A4 in vitro using a single point IC50. J Biomol Screen 2002;7:373-382.